Erişkin Onkoloji Hastalarında Kan Transfüzyonu Yönetimi: Hemoglobin Eşik Değerleri ve Endikasyonlar
Özet
Erişkin onkoloji hastalarında anemi, yaşam kalitesini düşüren ve mortaliteyi artıran yaygın bir problemdir. Geçmişte hemoglobin seviyesini yüksek tutmayı amaçlayan "10/30 kuralı" uygulanırken, güncel veriler maliyet ve enfeksiyon riskleri nedeniyle daha az kan kullanımını içeren "restriktif (kısıtlayıcı)" stratejileri öne çıkarmaktadır. Hemodinamik olarak stabil onkoloji hastalarında transfüzyon için hemoglobin eşik değeri genellikle 7-8 g/dL kabul edilmektedir. Transfüzyon kararı verilirken sadece laboratuvar değerlerine değil; hastanın semptomlarına, kardiyovasküler komorbiditelerine ve trombositopeni durumuna bütünsel bakılmalıdır. Kan transfüzyonları hemoglobin seviyesinde hızlı artış sağlasa da alerjik reaksiyonlar, akut akciğer hasarı (TRALI), dolaşımsal aşırı yüklenme (TACO) ve kronik transfüzyonlarda organ hasarına yol açan demir birikimi (hemosiderozis) gibi ciddi immün ve immün olmayan riskler barındırmaktadır. Bu nedenle, klinisyenlerin her hastayı bireysel risk-fayda dengesinde değerlendirmesi, gereksiz uygulamalardan kaçınması ve aktif kanaması olmayan hastalara tek seferde bir ünite eritrosit transfüzyonu yaparak süreci yakından izlemesi önerilmektedir.
Anemia in adult oncology patients is a common problem that decreases the quality of life and increases mortality. While the "10/30 rule," which aimed to keep hemoglobin levels high, was applied in the past, current data highlight "restrictive" strategies involving less blood utilization due to costs and infection risks. The hemoglobin threshold for transfusion in hemodynamically stable oncology patients is generally accepted as 7-8 g/dL. When making a transfusion decision, clinicians should not focus solely on laboratory values but must holistically consider the patient's symptoms, cardiovascular comorbidities, and thrombocytopenia status. Although blood transfusions provide a rapid increase in hemoglobin levels, they carry serious immune and non-immune risks such as allergic reactions, acute lung injury (TRALI), circulatory overload (TACO), and iron accumulation (hemosiderosis) leading to organ damage in chronic transfusions. Therefore, it is recommended that clinicians evaluate each patient within an individual risk-benefit balance, avoid unnecessary practices, and closely monitor the process by administering a single unit of erythrocyte transfusion at a time to patients without active bleeding.
Referanslar
Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European journal of cancer. 2004;40(15):2293-2306.
Radziwon P, Krzakowski M, Kalinka E, et al. Anemia in cancer patients—Expert Group recommendations. Revision 2020. Oncology in Clinical Practice. 2020;16(5):261-269.
Vincent J-L, De Backer D. Oxygen transport—the oxygen delivery controversy. Intensive care medicine. 2004;30(11):1990-1996.
Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane database of systematic reviews. 2016(10).
Roubinian NH, Murphy EL, Mark DG, et al. Long-term outcomes among patients discharged from the hospital with moderate anemia: a retrospective cohort study. Annals of internal medicine. 2019;170(2):81-89.
Roubinian NH, Escobar GJ, Liu V, et al. Decreased red blood cell use and mortality in hospitalized patients. JAMA internal medicine. 2014;174(8):1405-1407.
Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. New England Journal of Medicine. 2011;365(26):2453-2462.
Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. Effect of a restrictive vs liberal blood transfusion strategy on major cardiovascular events among patients with acute myocardial infarction and anemia: The REALITY Randomized Clinical Trial. JAMA. 2021;325(6):552-560.
Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New England Journal of Medicine. 1999;340(6):409-417.
Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. New England Journal of Medicine. 2013;368(1):11-21.
Hajjar LA, Vincent J-L, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. Jama. 2010;304(14):1559-1567.
Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. New England Journal of Medicine. 2017;377(22):2133-2144.
Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. Annals of internal medicine. 2019;171(11):805-822.
Heyes J, Kelly PA, Monaghan K, et al. A single unit transfusion policy reduces red cell transfusions in general medical in-patients. QJM: An International Journal of Medicine. 2017;110(11):735-739.
King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion. 2004;44(1):25-29.
Stanworth SJ, Navarrete C, Estcourt L, et al. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. British journal of haematology. 2015;171(3):297-305.
St. Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861.
Martí‐Carvajal AJ, Sola I, González LE, et al. Pharmacological interventions for the prevention of allergic and febrile non‐haemolytic transfusion reactions. Cochrane database of systematic reviews. 2010(6).
Rodgers GM, Becker PS, Blinder M, et al. Cancer-and chemotherapy-induced anemia. Journal of the National Comprehensive Cancer Network. 2012;10(5):628-653.
Jefferies S, Rajan B, Ashley S, et al. Haematological toxicity of cranio-spinal irradiation. Radiotherapy and oncology. 1998;48(1):23-27.
Palla AR, Kennedy D, Mosharraf H, et al. Autoimmune hemolytic anemia as a complication of nivolumab therapy. Case reports in oncology. 2016;9(3):691-697.
Nair R, Gheith S, Nair SG. Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. New England Journal of Medicine. 2016;374(11):1096-1097.
Wiesen AR, Hospenthal DR, Byrd JC, et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Annals of internal medicine. 1994;121(4):278-280.
Kader AS, Lim JT, Berthelet E, et al. Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy. American journal of clinical oncology. 2007;30(5):492-497.
Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86(8):1528-1536.
Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. Jama. 2016;316(19):2025-2035.
Prescott LS, Taylor JS, Lopez-Olivo MA, et al. How low should we go: a systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology. Cancer treatment reviews. 2016;46:1-8.
Uhl L, Assmann SF, Hamza TH, et al. Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood, The Journal of the American Society of Hematology. 2017;130(10):1247-1258.
